Synergistic O
effects O
of O
marijuana O
abuse O
and O
HIV O
infection O
on O
neural O
activation O
during O
a O
cognitive O
interference O
task O
Marijuana O
use O
, O
which O
is O
disproportionately O
prevalent O
among O
HIV-infected O
persons O
, O
can O
alter O
activity O
in O
fronto-parietal O
regions O
during O
cognitively O
demanding O
tasks O
. O

While O
HIV O
is O
also O
associated O
with O
altered O
neural O
activation O
, O
it O
is O
not O
known O
how O
marijuana O
may O
further O
affect O
brain O
function O
in O
this O
population O
. O

Our O
study O
examined O
the O
independent O
and O
additive O
effects O
of O
HIV O
infection O
and O
regular O
marijuana O
use O
on O
neural O
activation O
during O
a O
cognitive O
interference O
task O
. O

The O
sample O
included O
93 O
adults O
who O
differed O
on O
marijuana O
and O
HIV O
statuses O
( O
20 O
MJ+/HIV+ O
, O
19 O
MJ+/HIV− O
, O
29 O
MJ−/HIV+ O
, O
25 O
MJ−/HIV− O
) O
. O

Participants O
completed O
a O
counting O
Stroop O
task O
during O
a O
functional O
magnetic O
resonance O
imaging O
scan O
. O

Main O
and O
interactive O
effects O
on O
neural O
activation O
during O
interference O
versus O
neutral O
blocks O
were O
examined O
using O
a O
mixed-effects O
analysis O
. O

The O
sample O
showed O
the O
expected O
Stroop O
effect O
for O
both O
speed O
and O
accuracy O
. O

There O
were O
main O
effects O
of O
MJ O
in O
the O
right O
and O
left O
inferior O
parietal O
lobules O
, O
with O
the O
left O
cluster O
extending O
into O
the O
posterior O
middle O
temporal O
gyrus O
, O
and O
a O
main O
effect O
of O
HIV O
in O
the O
dorsal O
anterior O
cingulate O
cortex O
. O

There O
was O
an O
interaction O
in O
the O
left O
fronto-insular O
cortex O
, O
such O
that O
the O
MJ+/HIV+ O
group O
had O
the O
largest O
increase O
in O
activation O
compared O
to O
other O
groups O
. O

Among O
MJ+ O
, O
signal O
change O
in O
this O
cluster O
correlated O
positively O
with O
cumulative O
years O
of O
regular O
marijuana O
use O
. O

These O
results O
suggest O
that O
comorbid O
HIV O
and O
marijuana O
use O
is O
associated O
with O
complex O
neural O
alterations O
in O
multiple O
brain O
regions O
during O
cognitive O
interference O
. O

Follow-up O
research O
is O
needed O
to O
determine O
how O
marijuana-related O
characteristics O
may O
moderate O
HIV O
neurologic O
disease O
and O
impact O
real-world O
functioning O
. O

Materials O
and O
Methods O
Participants O
The O
sample O
included O
93 O
adults O
aged O
18–55 O
years O
who O
were O
active O
marijuana O
users O
with O
HIV O
( O
MJ+/HIV+ O
, O
n= O
20 O
) O
and O
without O
HIV O
( O
MJ+/HIV− O
, O
n= O
19 O
) O
or O
non-marijuana O
users O
with O
HIV O
( O
MJ−/HIV+ O
, O
n= O
29 O
) O
and O
without O
HIV O
( O
MJ−/HIV− O
, O
n= O
25 O
) O
. O

The O
MJ+ O
groups O
met O
the O
following O
criteria O
: O
≥4 O
days O
of O
marijuana O
use O
in O
the O
past O
month O
and O
≥1 O
year O
of O
regular O
marijuana O
use O
[ O
i.e. O
, O
consistent O
use O
at O
a O
frequency O
of O
≥3 O
or O
more O
days O
per O
week O
] O
. O

The O
MJ− O
groups O
met O
the O
following O
criteria O
: O
no O
lifetime O
cannabis O
use O
disorder O
, O
no O
history O
of O
regular O
marijuana O
use O
, O
0 O
days O
of O
marijuana O
use O
in O
the O
past O
90 O
days O
, O
and O
a O
THC-negative O
drug O
screen O
. O

Alcohol O
and O
nicotine O
use O
were O
permitted O
in O
all O
groups O
, O
but O
participants O
could O
not O
have O
current O
alcohol O
dependence O
. O

Participants O
also O
could O
have O
no O
history O
of O
abusing O
other O
drugs O
, O
including O
cocaine O
, O
amphetamine O
, O
benzodiazepines O
, O
and O
opioids O
, O
as O
defined O
by O
any O
of O
the O
following O
: O
history O
of O
regular O
use O
, O
lifetime O
dependence O
, O
use O
in O
the O
past O
30 O
days O
, O
or O
positive O
drug O
screen O
. O

HIV-negative O
status O
was O
verified O
by O
an O
OraQuick© O
rapid O
test O
, O
and O
self-reported O
HIV-positive O
status O
was O
verified O
by O
medical O
record O
review O
. O

Additional O
exclusion O
criteria O
were O
: O
English O
non-fluency O
or O
illiteracy O
; O
< O
8th O
grade O
education O
; O
severe O
learning O
disability O
; O
serious O
neurological O
disorders O
not O
due O
to O
HIV O
; O
acute O
opportunistic O
brain O
infections O
or O
history O
of O
such O
infections O
without O
return O
to O
normal O
cognition O
; O
severe O
head O
trauma O
with O
loss O
of O
consciousness O
> O
30 O
minutes O
and O
persistent O
functional O
decline O
; O
severe O
mental O
illness O
; O
current O
use O
of O
antipsychotic O
or O
mood O
stabilizing O
medications O
; O
MRI O
contraindications O
; O
and O
impaired O
mental O
status O
. O

Procedures O
Data O
were O
collected O
as O
part O
of O
two O
concurrent O
neuroimaging O
studies O
on O
drug O
abuse O
and O
HIV O
that O
had O
shared O
sampling O
and O
assessment O
procedures O
. O

Participants O
were O
recruited O
via O
advertisements O
in O
local O
newspapers O
, O
websites O
, O
community-based O
organizations O
, O
and O
infectious O
diseases O
clinics O
. O

After O
passing O
a O
brief O
pre-screener O
, O
individuals O
completed O
an O
in-person O
screening O
. O

Eligible O
participants O
returned O
for O
the O
MRI O
scan O
and O
additional O
assessments O
. O

Participants O
were O
asked O
to O
abstain O
from O
marijuana O
use O
for O
> O
4 O
hours O
prior O
to O
the O
scan O
; O
the O
mean O
number O
of O
hours O
since O
last O
use O
was O
23.36 O
( O
SD= O
13.44 O
) O
. O

All O
study O
groups O
were O
represented O
in O
each O
protocol O
. O

Although O
not O
statistically O
significant O
( O
X O
( O
3 O
) O
2= O
7.27 O
, O
p= O
.06 O
) O
, O
MJ+/HIV− O
was O
underrepresented O
( O
8 O
% O
vs. O
25 O
% O
) O
and O
MJ−/HIV+ O
was O
overrepresented O
( O
50 O
% O
vs. O
25 O
% O
) O
in O
the O
first O
protocol O
. O

Therefore O
, O
protocol O
was O
controlled O
for O
in O
analyses O
. O

Procedures O
were O
approved O
by O
the O
institutional O
review O
boards O
at O
Duke O
University O
and O
University O
of O
North O
Carolina O
at O
Chapel O
Hill O
. O

Measures O
Participants O
completed O
clinical O
interviews O
, O
questionnaires O
, O
urine O
drug O
screening O
, O
and O
pregnancy O
tests O
. O

Module O
E O
of O
the O
Structured O
Clinical O
Interview O
for O
DSM-IV-TR O
identified O
current O
and O
past O
substance O
use O
disorders O
, O
and O
the O
Addiction O
Severity O
Index-Lite O
assessed O
history O
of O
substance O
use O
and O
associated O
impairments O
. O

Timeline O
follow-back O
methodology O
was O
used O
to O
assess O
substance O
use O
in O
the O
past O
90 O
days O
at O
both O
the O
screening O
and O
MRI O
visits O
. O

The O
Wechsler O
Test O
of O
Adult O
Reading O
estimated O
premorbid O
verbal O
IQ O
. O

The O
Stroop O
Color O
and O
Word O
Test O
was O
used O
to O
assess O
executive O
functioning O
, O
and O
published O
norms O
were O
used O
to O
convert O
raw O
interference O
scores O
to O
demographically O
corrected O
T-score O
. O

An O
audio O
computer-assisted O
self-interview O
assessed O
demographics O
, O
smoking O
behavior O
, O
and O
medical O
history O
. O

Healthcare O
records O
were O
reviewed O
to O
confirm O
no O
exclusionary O
neurologic O
, O
psychiatric O
, O
or O
medical O
conditions O
. O

For O
HIV+ O
participants O
, O
we O
abstracted O
HIV O
disease O
indicators O
, O
including O
date O
of O
diagnosis O
and O
CD4 O
cell O
counts O
. O

fMRI O
counting O
Stroop O
Task O
The O
counting O
Stroop O
is O
a O
cognitive O
interference O
task O
that O
was O
designed O
for O
administration O
during O
MRI O
. O

Participants O
were O
presented O
alternating O
blocks O
of O
neutral O
and O
interference O
trials O
. O

During O
each O
trial O
, O
the O
same O
word O
was O
listed O
vertically O
1–4 O
times O
, O
and O
participants O
were O
instructed O
to O
indicate O
as O
quickly O
as O
possible O
the O
number O
of O
words O
using O
a O
response O
pad O
. O

Interference O
trials O
consisted O
of O
number O
words O
( O
one O
, O
two O
, O
three O
, O
or O
four O
) O
, O
while O
neutral O
trials O
consisted O
of O
animal O
words O
( O
dog O
, O
cat O
, O
mouse O
, O
and O
bird O
) O
; O
the O
conditions O
were O
balanced O
for O
word O
length O
. O

Each O
block O
contained O
six O
randomly O
selected O
trials O
that O
were O
presented O
for O
1.5s O
, O
and O
there O
was O
a O
0.75s O
fixed O
interval O
between O
trials O
during O
which O
a O
crosshair O
was O
displayed O
. O

The O
single O
4-minute O
run O
consisted O
of O
16 O
alternating O
interference O
and O
neutral O
blocks O
, O
with O
the O
initial O
block O
type O
randomized O
across O
participants O
. O

Prior O
to O
the O
fMRI O
session O
, O
participants O
were O
trained O
on O
the O
task O
to O
ensure O
comprehension O
. O

MRI O
data O
acquisition O
MRI O
data O
were O
acquired O
using O
a O
3.0T O
GE O
MR750 O
scanner O
with O
an O
8-channel O
head O
coil O
. O

High-resolution O
T O
1-weighted O
structural O
images O
were O
acquired O
with O
the O
following O
parameters O
: O
TR= O
8.1ms O
; O
TE= O
3.18ms O
; O
FOV= O
25.6cm O
; O
matrix= O
256 O
* O
256 O
; O
slice O
thickness= O
1mm O
; O
voxel O
size= O
1mm3 O
; O
and O
number O
of O
slices= O
172 O
. O

Whole-brain O
blood-oxygen-level-dependent O
( O
BOLD O
) O
images O
were O
collected O
using O
high-throughput O
T2 O
* O
-weighted O
echo-planar O
imaging O
in O
the O
axial O
plane O
. O

Parameters O
for O
the O
two O
protocols O
were O
the O
same O
( O
TR= O
2000ms O
; O
FOV= O
240 O
; O
matrix= O
64 O
* O
64 O
; O
slice O
thickness= O
3.8mm O
; O
voxel O
resolution= O
3.75mm O
× O
3.75mm O
× O
3.79mm O
) O
, O
except O
there O
were O
slight O
differences O
for O
TE O
( O
27ms O
vs. O
25ms O
) O
and O
number O
of O
slices O
( O
35 O
and O
39 O
) O
. O

Interleaved O
images O
covered O
the O
entire O
brain O
. O

There O
was O
no O
difference O
in O
signal-to-fluctuation O
noise O
ratio O
( O
SFNR O
) O
between O
protocols O
[ O
141.33 O
± O
33.13 O
vs. O
142.57 O
± O
22.48 O
; O
t O
( O
91 O
) O
= O
0.21 O
, O
p= O
.84 O
] O
. O

This O
measure O
of O
temporal O
intensity O
stability O
reflects O
factors O
like O
scanner O
and O
electronics O
noise O
, O
head O
motion O
, O
and O
physiological O
changes O
. O

Quality O
control O
From O
99 O
study O
completers O
, O
3 O
were O
excluded O
for O
poor O
task O
performance O
indicative O
of O
inattention O
across O
multiple O
blocks O
( O
defined O
as O
mean O
accuracy O
of O
< O
67 O
% O
on O
neutral O
blocks O
) O
. O

Three O
additional O
participants O
were O
excluded O
for O
SFNR O
< O
75 O
. O

In O
the O
final O
sample O
( O
N=93 O
) O
, O
all O
participants O
had O
a O
relative O
mean O
displacement O
of O
< O
0.20mm O
( O
M= O
0.053mm O
, O
SD= O
0.035 O
) O
. O

DVARS O
, O
an O
index O
of O
the O
rate O
of O
change O
of O
BOLD O
signal O
across O
the O
brain O
at O
each O
frame O
of O
data O
, O
was O
also O
calculated O
using O
the O
motion O
outliers O
tool O
in O
FMRIB O
’ O
s O
Software O
Library O
( O
FSL O
) O
v6.00 O
. O

A O
2×2 O
between-subjects O
ANOVA O
revealed O
no O
main O
effects O
of O
HIV O
[ O
F O
( O
1,89 O
) O
= O
0.04 O
, O
p= O
.84 O
) O
or O
MJ O
[ O
F O
( O
1,89 O
) O
= O
0.18 O
, O
p= O
.68 O
) O
and O
no O
interaction O
effect O
[ O
F O
( O
1,89 O
) O
= O
0.04 O
, O
p= O
.84 O
] O
for O
DVARS O
. O

Six O
motion O
parameters O
calculated O
using O
FSL O
’ O
s O
MCFLIRT O
were O
included O
as O
regressors O
of O
no O
interest O
in O
first O
level O
analyses O
to O
control O
for O
linear O
movement O
across O
the O
run O
, O
and O
DVARS O
was O
included O
in O
third O
level O
analyses O
to O
control O
for O
individual O
differences O
in O
motion O
. O

fMRI O
Data O
Analysis O
The O
functional O
and O
anatomical O
data O
were O
pre-processed O
and O
analyzed O
using O
FSL O
’ O
s O
FEAT O
. O

Preprocessing O
steps O
included O
: O
motion O
correction O
with O
MCFLIRT O
; O
slice-timing O
correction O
using O
Fourier-space O
time-series O
phase-shifting O
; O
spatial O
smoothing O
with O
a O
Gaussian O
kernel O
of O
5mm O
full-width O
at O
half-maximum O
; O
high-pass O
temporal O
filtering O
( O
Gaussian-weighted O
least O
squares O
straight O
line O
fitting O
with O
σ= O
50s O
) O
; O
grand-mean O
intensity O
normalization O
of O
the O
entire O
4D O
dataset O
by O
a O
single O
multiplicative O
factor O
; O
and O
skull O
stripping O
of O
structural O
images O
with O
BET O
. O

Registration O
of O
functional O
data O
to O
the O
T1-weighted O
anatomical O
slices O
and O
registration O
of O
structural O
images O
to O
the O
2mm O
Montreal O
Neurological O
Institute O
( O
MNI O
) O
standard-space O
template O
were O
done O
with O
FLIRT O
using O
a O
12-parameter O
affine O
transformation O
. O

Individual O
time-series O
statistical O
analysis O
was O
carried O
out O
using O
FILM O
with O
local O
autocorrelation O
correction O
. O

The O
interference O
blocks O
, O
serving O
as O
the O
regressor O
, O
were O
convolved O
with O
a O
double-gamma O
hemodynamic O
response O
function O
. O

Statistical O
contrasts O
of O
the O
interference O
condition O
compared O
to O
the O
implicitly O
modeled O
neutral O
condition O
were O
conducted O
using O
a O
fixed- O
effects O
analysis O
. O

For O
visualization O
, O
task O
activation O
maps O
for O
all O
participants O
combined O
were O
generated O
using O
FSL O
’ O
s O
Local O
Analysis O
of O
Mixed O
Effects O
( O
FLAME O
1+2 O
) O
with O
a O
stringent O
cluster O
threshold O
of O
Z O
> O
3.5 O
and O
p O
< O
.05 O
, O
corrected O
over O
the O
entire O
brain O
using O
Gaussian O
random O
field O
theory O
. O

A O
2-factor O
between-subjects O
general O
linear O
model O
( O
GLM O
) O
, O
implemented O
using O
FLAME O
1+2 O
, O
was O
used O
to O
identify O
main O
and O
interaction O
effects O
of O
marijuana O
and O
HIV O
. O

Age O
, O
education O
, O
DVAR O
, O
and O
protocol O
were O
entered O
as O
covariates O
. O

In O
FSL O
, O
the O
interaction O
is O
modeled O
as O
a O
2-group O
comparison O
; O
in O
this O
case O
, O
the O
combined O
effects O
of O
MJ+/HIV+ O
and O
MJ−/HIV− O
were O
compared O
to O
the O
combined O
effects O
of O
MJ+/HIV− O
and O
MJ−/HIV+ O
. O

This O
model O
was O
cluster O
thresholded O
at O
Z O
> O
2.3 O
and O
a O
corrected O
cluster O
significance O
level O
of O
p O
< O
.05 O
. O

For O
all O
analyses O
, O
the O
Harvard-Oxford O
cortical O
and O
subcortical O
structural O
atlases O
were O
used O
to O
identify O
regions O
within O
significant O
clusters O
. O

For O
each O
significant O
cluster O
identified O
in O
the O
ANOVA O
, O
percent O
signal O
change O
was O
extracted O
using O
Featquery O
. O

Further O
analyses O
were O
conducted O
in O
SPSS O
24.0 O
. O

Group O
averages O
were O
examined O
to O
determine O
the O
direction O
of O
effects O
. O

Pearson O
partial O
correlation O
tests O
were O
run O
to O
examine O
the O
relation O
of O
signal O
change O
to O
clinical O
variables O
( O
cumulative O
years O
of O
marijuana O
use O
among O
MJ+ O
participants O
and O
nadir O
CD4 O
count O
among O
HIV+ O
participants O
) O
. O

These O
correlations O
controlled O
for O
age O
, O
education O
, O
DVAR O
, O
and O
protocol O
. O

